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Abstract
Background: Acute quadriplegic myopathy (AQM) or critical illness myopathy (CIM) is frequently observed in
intensive care unit (ICU) patients. To elucidate duration-dependent effects of the ICU intervention on molecular
and functional networks that control the muscle wasting and weakness associated with AQM, a gene expression
profile was analyzed at time points varying from 6 hours to 14 days in a unique experimental rat model mimicking
ICU conditions, i.e., post-synaptically paralyzed, mechanically ventilated and extensively monitored animals.
Results: During the observation period, 1583 genes were significantly up- or down-regulated by factors of two or
greater. A significant temporal gene expression pattern was constructed at short (6 h-4 days), intermediate (5-8
days) and long (9-14 days) durations. A striking early and maintained up-regulation (6 h-14d) of muscle atrogenes
(muscle ring-finger 1/tripartite motif-containing 63 and F-box protein 32/atrogin-1) was observed, followed by an
up-regulation of the proteolytic systems at intermediate and long durations (5-14d). Oxidative stress response
genes and genes that take part in amino acid catabolism, cell cycle arrest, apoptosis, muscle development, and
protein synthesis together with myogenic factors were significantly up-regulated from 5 to 14 days. At 9-14 d,
genes involved in immune response and the caspase cascade were up-regulated. At 5-14d, genes related to
contractile (myosin heavy chain and myosin binding protein C), regulatory (troponin, tropomyosin), developmental,
caveolin-3, extracellular matrix, glycolysis/gluconeogenesis, cytoskeleton/sarcomere regulation and mitochondrial
proteins were down-regulated. An activation of genes related to muscle growth and new muscle fiber formation
(increase of myogenic factors and JunB and down-regulation of myostatin) and up-regulation of genes that code
protein synthesis and translation factors were found from 5 to 14 days.
Conclusions: Novel temporal patterns of gene expression have been uncovered, suggesting a unique, coordinated
and highly complex mechanism underlying the muscle wasting associated with AQM in ICU patients and
providing new target genes and avenues for intervention studies.
Background
All critically ICU patients suffer from severe wasting and
impaired muscle function, which delay respirator wean-
ing and persist long after hospital discharge; thus redu-
cing quality of life [1,2]. Although muscle wasting in
ICU patients may be related to the primary disease, it
also devolves from the interventions used in modern
anaesthesiology and intensive care: Prolonged mechani-
cal ventilation, post-synaptic neuromuscular
transmission blockade (NMB), sedation, and systemic
corticosteroid hormone treatment have all been pro-
posed as factors triggering the severe muscle wasting,
paralysis, impaired respiratory function, and partial or
complete loss of the motor protein myosin in ICU
patients who develop Acute Quadriplegic Myopathy
(AQM). Sepsis, organ transplantation, multi-organ fail-
ure, and hyperglycemia are also hypothesized risk fac-
tors for AQM [3-6]. We have recently demonstrated
that complete mechanical silencing, i.e., absence of
weight bearing and internal strain in the muscle caused
by muscle contraction, induces a phenotype which clo-
sely resembles that of AQM in ICU patients [7]. The
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myosin loss and muscle wasting follows a temporal
sequence with an initial sparing of both muscle function,
mass and myosin content followed by a progressive loss
of muscle force that exceeds the loss in muscle mass
due to a preferential loss of the motor protein myosin
[7-9].
Acute quadriplegic myopathy, also known as critical
illness myopathy (CIM), thick filament myosin myopa-
thy, acute myopathy in severe asthma and myopathy of
intensive care [3], was for many years considered to be
rare and of limited clinical significance, but in the past
two decades the number of reported cases with AQM
has substantially increased. Recent studies show that
approximately 50% of ICU patients with sepsis, multi-
organ failure or prolonged mechanical ventilation pre-
sent significant neuromuscular dysfunction [10]. This
muscle wasting and weakness may persist 5 years after
hospital discharge, drastically impairing quality of life of
survivors as well as increasing morbidity and financial
costs [1,11,12].
There is a strong interest in the fundamental molecu-
lar mechanism of muscle atrophy, including the com-
plex and highly ordered mechanisms of protein
synthesis and degradation, the suppression of mitochon-
drial related bioenergetic pathways, cell proliferation and
differentiation, and oxidative stress [13,14]. In AQM,
muscle wasting involves the activation of three proteoly-
tic systems: ubiquitin-proteasome, autophagy-lysosome,
and the calcium-dependent calpains, as well as inactiva-
tion of specific Na channels, activation of the TGF-b/
MAPK cascade, and apoptotic pathways [15,16]; how-
ever, how and when these mechanisms are activated
remain poorly understood.
There are several independent factors that complicate
the study of mechanisms underlying the muscle wasting
and loss of muscle function in ICU patients with AQM,
such as differences in primary disease, different pharma-
cological treatments, exposure to different causative
agents, and delay of muscle biopsies until several weeks
after ICU admission. To effectively unravel underlying
mechanisms, experimental animal models mimicking the
ICU intervention are needed. The most common animal
model used to date is a rat model with unilateral periph-
eral denervation of one hind limb combined with high
levels of systemic corticosteroid administration [17,18];
other models of disuse and muscle unloading are hind
limb suspension, spaceflight, joint immobilization, and
spinal cord isolation [19-22]. All these experimental
models induce muscle atrophy, but lack significant com-
ponents of muscle wasting seen in ICU patients due to
deep sedation or NMB, such as long-term mechanical
ventilation and mechanical silencing caused by lack of
weight bearing, and the internal strain produced by acti-
vation of contractile elements. There is accordingly a
strong demand of an experimental ICU model mimicking
ICU conditions, i.e., key factors essential for the muscle
wasting and paralysis in ICU patients who develop AQM
[23]. We have previously used a porcine ICU model, in
which piglets are mechanically ventilated and exposed to
NMB, corticosteroids and/or sepsis for 5 days [24]. This
model has given us valuable information regarding the
effects of these different triggering factors separately or
in combination during the early phase of the disease [8];
but, this model also has disadvantages such as high cost,
and logistic problems that limit the duration of the
experiments and the study of proteins with a slow turn-
over rate such as contractile proteins.
In order to improve our understanding of duration-
dependent effects of the ICU intervention on molecular
and functional networks that control the muscle wasting
and weakness, we have used a unique experimental rat
model that mimics the ICU condition. This model
includes key elements such as mechanical ventilation,
mechanical silencing, NMB and extensive monitoring
for durations varying from 6 hours to 14 days, without
the confounding influences of differences in systemic
disease and pharmacological treatment. Gene array ana-
lyses with this model reveal that, in response to the ICU
intervention, there is a complex, unique, and highly
coordinated activation of protein synthesis, degradation,
protective mechanisms, and intracellular signalling.
Results
Out of 26,209 probe sets on the array, 1583 were signifi-
cantly up- or down-regulated in at least one of the 0.25-
4, 5-8 and 9-14 day groups compared with the control
group. 128, 1182 and 1115 gene probes passed the cut-
off criteria (minimum ± 2 fold change with adjusted p-
value < 0.05) in the 0.25-4, 5-8 and 9-14d groups,
respectively. The dramatic increase of differentially
expressed genes in the 5-8d and 9-14d groups compared
with the 0.25-4d group agrees with the marked gastro-
cnemius muscle loss, i.e., 40% in the 5-8d and 51% in
the 9-14d groups compared with the modest 11% mus-
cle mass loss in the 0.25-4d group.
The Venn diagram shows overlapping genes at the
three durations (Figure 1). Only 68 differentially
expressed genes were common in all three groups.
Further, there was little overlap between the pairs 0.25-
4d - 5-8d and 0.25-4d - 9-14d groups (83 and 79 genes
respectively), while 747 genes overlapped between the 5-
8 and 9-14d groups, indicating that these two groups
shared almost half of the 1583 significantly regulated
genes.
K-means cluster analysis
Results of K-means clustering analysis, separating the
1583 differentially expressed genes into 12 clusters,
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allowed the reconstruction of different temporal expres-
sion patterns (Figure 2). Each data point represents the
average expression (log2 ratio) value at different time
points (0.25-4d, 5-8d and 9-14d).
Clusters 1, 10, 11 and 12 contained up-regulated
genes. Cluster 10 had 79 genes with an early (0.25-4d)
and sustained response (5-8d) of 2-fold change (log21),
decreasing slightly at the last time point (9-14d). Atro-
genes (muscle ring-finger 1/tripartite motif-containing
63 (Murf1/Trim63) and F-box protein 32/atrogin-1
(Fbox32/atrogin-1)) and their regulator, forkhead box
O1 (Foxo1), were in this cluster. Cluster 12 had by far
the largest number of genes (542) with a maintained up-
regulation around 2-fold (log21) from 5 to 14 days.
These genes are involved in proteolysis (ubiquitin-pro-
teasome, calpain and autophagy-lysosome systems),
apoptosis, DNA repair, protein synthesis, endoplasmic
reticulum-associated degradation (ERAD), antioxidant
and oxidative stress response genes, amino acid regula-
tion and chaperone activity. Cluster 11 had 63 genes
up-regulated from 5 to 14 days, but unlike cluster 12,
they were highly expressed with an average 8-fold
change (log23). These genes belong to muscle develop-
ment, cell cycle arrest, metallothioneins and autophagy-
lysosome system. Cluster 1 contained 205 genes which
were only up-regulated at the longest duration (9-14d),
i.e., genes mainly involved in immune response and
apoptosis.
The remaining clusters represented different expres-
sion patterns of down-regulated genes during the time
course. Clusters 4, 5, 6, 8 and 9 presented an early sig-
nificant decline in expression response (0.25-4d) that
was maintained at the longer durations (from 5 to 14
days). Clusters 6 and 8 included 6 and 26 down-regu-
lated genes involved in muscle contraction (the b/slow
and the fast IIa myosin heavy chains (MyHC-beta/Myh7
and MyHC-IIa/Myh2) and myosin light chain 2 and 3
(MyLC2/Myl2 and MyLC3/Myl3), that were significantly
down-regulated between 2- and 3-fold (log2 (-1) and
log2 (-1.5)) at 0.25-4d, continued to declined more than
8-fold (log2(-3)) from 5 to 14 days. Clusters 5 and 9
included 174 and 54 genes respectively, well represented
by growth factors, control of cell cycle and regulation of
proliferation and differentiation with a 2-fold down-reg-
ulation at 0.25-4d (log2 (-1)) and a moderate decline
(between 2 and 4-fold change) at intermediate and long
durations (5-14d). Five genes were grouped into cluster
4, but they did not share any functional characteristic.
Clusters 2, 3 and 7 showed a significant down-regulation
of gene expression at the two longest durations (5-14d).
Cluster 7 included 90 down-regulated genes showing
around 4-fold change (log2 (-2)), mainly genes involved
in developmental processes and genes coding some sar-
comeric and extracellular matrix proteins. Clusters 2
and 3 included 152 and 187 genes respectively, down-
regulated 2-fold, i.e., glycolysis/gluconeogenesis, respira-
tory chain, tricarboxylic acid (TCA) cycle, extracellular
matrix structure, cell adhesion, developmental processes
and cytoskeleton/sarcomere genes.
In almost all clusters, there were genes of metabolism,
transport, signal transduction and transcription (detailed
Figure 1 Number of genes differentially expressed at short
(0.25-4d), intermediate (5-8d) and long (9-14d) durations.
Number of genes regulated at more than one time point are found
in overlapping regions. Upward arrows indicate up-regulation and
downward arrows indicate down-regulation.
Figure 2 Results from K-means cluster analysis. Genes were
divided into 12 clusters using a K-means cluster analysis algorithm,
which distinguishes sets of genes with similar expression profiles
with respect to time. Relative expression levels (log2 ratio) for each
gene and the average expression values (magenta line) are shown
at different time points (0.25-4d, 5-8d and 9-14d) compared to
control conditions.
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list of the genes in each cluster with associated func-
tional categories are listed in Additional file 1).
According to K-means clustering results, a graphical
summary of significant temporal gene expression pat-
terns at the different time points are shown in Figure 3.
Gene functional classification independent of K-means
clustering
In order to obtain more detailed temporal expression
patterns of individual genes belonging to the same func-
tional categories, genes were grouped together according
to their function independent of K-means clustering.
Ubiquitin-proteasome system (UPS)
Most Ub-proteasome genes were up-regulated 2-3-fold
at 5-8d, followed by a slight decrease at 9-14d. The two
muscle-specific E3 ligases, atrogin-1/Fbox32 and Murf1/
Trim63 showed an early (0.25-4d) and sustained (5-14d)
2-3-fold up-regulation.
Autophagy-lysosome system
The lysosomal proteases, cathepsins (Ctsl1, Ctss and
Lgmn) were up-regulated at different time points. Ctsl1
showed an early up-regulation (0.25-4d) and increased
to more than 10-fold from 5 to 14 days while legumain
(Lgmn) and Ctss showed a later and lower (2-3-fold)
expression response. The microtubule-associated protein
1 light chain 3 beta (Map1lc3b), playing an essential
role for formation of authophagosomes, was up-regu-
lated 2-3-fold during the whole course of the interven-
tion. Runt related transcription factor 1 (Runx1) and
cathepsin inhibitors (cystatins (Cst)) showed a more
than 10-fold up-regulation from 5 to 14 days.
Calpain system
Calpains, nonlysosomal calcium-dependent proteases,
were regulated from 5 to 14 days. Calpain 1 (Capn1)
did not change significantly, however, calpain 2 (Capn2)
was up-regulated ~2-fold while the muscle-specific iso-
form, calpain 3 (Capn3), was down-regulated (5-14d).
Endoplasmic reticulum-associated degradation (ERAD)
ER degradation enhancer, mannosidase alpha-like 1 and
2 (Edem1, Edem2), ER lipid raft associated 1 (Erlin1),
UBX domain protein 4 (Ubx4) and Der1-like domain
family member 2 were up-regulated ~2-fold from 5 to
14 days.
Sarcomeric proteins
These were down-regulated mainly from 5 to 14 days
with the exception of the up-regulation of myosin bind-
ing protein H (Mybph). Genes coding the b/slow and
the fast IIa MyHC isoforms (Myh7 and Myh2) and regu-
latory (Myl2) and essential (Myl3) myosin light chains
showed a 2-3-fold down-regulation from 6 h to 4 days,
but did not pass the cut-off adjusted p-value <0.05.
From 5 to 14 days, Myh7, Myh2, Myl2 and Myl3 were
dramatically down-regulated, i.e., 5-, 11-, 10-, and 6-fold
(5-8d) and 13-, 8-, 13- and 17-fold (9-14d), respectively.
Other sarcomeric proteins such as the contractile pro-
teins alpha cardiac myosin heavy chain 6 (Myh6), myo-
sin light chain kinase 2 (Mylk2) and myosin light chain
1 (Myl1), the actin associated regulatory proteins tropo-
myosin (Tpm3) and tropomodulin (Tmod4) and struc-
tural sarcomeric proteins, such as LIM domain, actinin,
myomesin and myozenin, were also down-regulated
from 5 to 14 days.
Extracellular matrix
Most extracellular matrix genes such as members of col-
lagen family, laminins (Lamb2, Lama2), fibulins and
microfibrillar associated proteins (Mfap4, Mfap3l,
Mfap5) among other proteins were down-regulated
from 5 to 14 days.
Protein synthesis
Eukaryotic translation initiation and elongation factors
were up-regulated 2-3-fold from 5 to 14 days as most
ribosomal proteins. The protein synthesis repressor,
eukaryotic translation initiation factor 4E binding pro-
tein 1 (Eif4ebp1) was up-regulated from 6h to 8 days
and followed by a dramatic decline from 9 to 14 days.
Oxidative stress response
There was a global activation of antioxidant and chemo-
protective genes during the course of the ICU interven-
tion. Heme oxygenase 1 (Hmox), aldehyde oxidase 1
(Aox1), beta polypeptide xanthine dehydrogenase (Xdh)
were up-regulated early (6h-4d) and sustained (5-14d)
while NAD(P)H dehydrogenase quinone 1 (Nqo1), bili-
verdin reductase B (Blvre), aldehyde dehydrogenase 3
family member A2 (Alh3a2) and several enzymes of the
glutathione S-transferase (GST) family were up-regu-
lated from 5 to 14 days. The metallothioneins 2a and 1
(Mt2a and Mt1) were up-regulated more than 8-fold at
0.25-4d, reaching more than 15-fold up-regulation at 9-
14d group.
Figure 3 Graphical summary of significant temporal gene
expression patterns according to K-means cluster analysis. Red
and blue arrows show up- and down-regulation, respectively. Thin
arrows indicate 2- to 4-fold change and thick arrows more than 4-
fold change of gene expression.
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Cellular cycle regulators
There was a noticeable up-regulation, especially from 5
to 14 days, of genes intervening in growth arrest, i.e.,
growth arrest and DNA-damage-inducible alpha
(Gadd45a),mediator of DNA damage checkpoint 1
(Mdc1), MAD2 mitotic arrest deficient-like 2 (yeast)
(Mad2l2), block of proliferation 1 (Bod1), genetic sup-
pressor element 1 (Gse1) and the growth inhibitors,
cyclin-dependent kinase inhibitor 2b, p15 (Cdknb2) and
cyclin-dependent kinase inhibitor 1a, p21 (Cdkna1).
The myelocytomatosis oncogene (Myc), stimulating
muscle growth-related genes and apoptosis, was up-
regulated 4-fold at all durations (0.25-14d).
Apoptosis
A late up-regulation was observed in the caspase cas-
cade at 9-14d, i.e., caspase-4 (Casp4) was up-regulated
2.5-fold and caspases 3, 1 and 12 (Casp3, Casp1 and
Casp12) did not pass ± 2-fold change cut-off, but its
expression was 1.7-fold higher. Other pro-apoptotic
genes such as programmed cell death 6 (Pdcd6), SIVA1
apoptosis-inducing factor (Siva1), BH3 interacting
domain death agonist (Bid), cell death-inducing DFFA-
like effector a (Cidea) and apoptosis antagonizing tran-
scription factor (Aatf) increased their expression from 5
to 14 days. In parallel with the activation of apoptosis,
the apoptotic repressor, nucleolar protein 3 (Nol3) and
the anti-apoptotic gene B-cell leukemia/lymphoma 2
related protein A1d (Bcl2a1d) were up-regulated 2-fold
at the longest duration (9-14d).
Heat shock proteins/chaperones
Heat shock proteins Hsp90aa1, Hspb8, cyclophilin A
(Ppia), and some members of DnaJ (Hsp40) family were
up-regulated 2-3-fold from 5 to 14 days. Heat shock
105kDa/110kDa protein (Hsph1) and translocase of
outer mitochondrial membrane 34 (Tomm34) increased
2-fold after 9 days. However, the muscle atrophy protec-
tive heat shock protein, alpha-crystallin-related B6
(Hspb6) and other chaperones were down-regulated
from 5 to 14 days.
Muscle development
Myogenin (Myog) was up-regulated 2-fold at 0.25-4
days, followed by a 13-fold increase (5-14d) and the
myogenic factors, Myf5 and Myf6, were up-regulated 3-
4-fold from 5 to 14 days. The inhibitor of DNA binding
2 (Id2) was up-regulated 2-fold at the longest duration.
The skeletal muscle receptor tyrosine kinase (Musk) was
gradually up-regulated during the time course of the
ICU intervention reaching 2.2-, 5.4- and 9.3-fold
increase at short, intermediate and long durations,
respectively.
Histone deacetylase 4 (Hdac4) that represses the mus-
cle transcription factor myocyte enhancer factor 2
(Mef2), being a contributor of muscle dysfunction [25],
increased around 3-fold at the 3 time points (0.25-14d).
Some genes implicated in muscle development and
growth also showed a significant down-regulation, such
as fibroblast growth factors 1, 2 and 6 (Fgf1, Fgf2, Fgf6),
supervillin (Svil) invoved in myosin II assembly and
focal adhesion and junctophilin (Jph1) were all down-
regulated at the intermediate and longest durations (5-
14d). Tripartife motif-containing 72 (Trim72), a muscle-
specific protein that plays a central role in cell mem-
brane repair, and vestigial like 2 (Drosophila) (Vgll2), a
cofactor of Mef2 and Tef1 required for skeletal muscle
differentiation, were down-regulated from 5 to 14 days.
Kyphoscoliosis peptidase (Ky), a cytoskeleton-associated
protease essential for normal muscle growth, maturation
and stabilization of neuromuscular junction and
required for a hypertrophic response in muscle [26], was
down-regulated 4-fold (0.25-4d), 30-fold (5-8d) and 15-
fold (9-14d).
Embigin homolog mouse (Emb) was recently identified
as a nerve terminal sprouting factor at the neuromuscu-
lar junction that is up-regulated in denervated muscle
[27]. Under ICU intervention, Emb was strongly up-
regulated from 5 to 14 days (36- and 59-fold change at
5-8d and 9-14d, respectively.
The muscle specific caveolin-3 (Cav3) was significantly
down-regulated 4.8-fold from 5 to 14 days.
Immune response
Many genes from this group, such as chemokines, anti-
gens, immunoglobulins, complement components, and
interferons, were primarily up-regulated at 9-14d.
Metabolism
Carbohydrates, lipids, fatty acids, aldehydes and steroids
metabolic genes and genes participating in glycolysis,
gluconeogenesis and mitochondria regulation (oxidative
phosphorylation, citric acid cycle) were down-regulated
from 5 to 14 days, while amino-acid metabolism was
up-regulated during the same time period.
Complete information (fold change, adjusted p-values)
and functional classification of genes previously men-
tioned and other differentially expressed genes involved
in transport, cytoskeleton structure and regulation,
mRNA processing, cell adhesion and genes that regulate
growth, proliferation, differentiation, transcription and
signalling are listed in Additional file 2.
Signalling pathways
List of differentially regulated genes with their corre-
sponding fold change and adjusted p-value at early
(0.25-4d), intermediate (5-8d) and long (9-14d) dura-
tions are shown in Table 1. The large majority of these
genes were significantly switched on from 5 to 14 days.
IGF1-AKT-FOXO signalling. Igf1r was up-regulated
around 2-fold (5-14d). Foxo1 was up-regulated 3-fold
only in the early phase (0.25-4d), promoting the up-reg-
ulation of atrogenes in this early period. Akt3 was up-
regulated 3.5-fold at the longest duration (9-14d).
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v-akt murine thymoma viral oncogene homolog 3 (protein kinase
B, gamma)
Akt3 1.1 7.7E-01 1.6 1.2E-02 2.5 2.9E-06
insulin-like growth factor 1 receptor Igf1r 1.2 1.2E-01 2.0 2.6E-06 1.8 4.5E-06
insulin-like growth factor 2 mRNA binding protein 2 Igf2bp2 1.1 8.1E-01 2.2 4.8E-05 1.6 2.5E-03
forkhead box O1 Foxo1 3.1 3.1E-04 1.2 6.4E-01 -1.1 7.0E-01
insulin-like growth factor binding protein 6 Igfbp6 -1.2 7.0E-01 -4.6 1.2E-04 -2.5 4.8E-03
insulin receptor substrate 1 Irs1 -1.9 2.9E-02 -4.2 8.4E-06 -3.9 2.4E-06
NF-kB signalling
ectodysplasin A2 receptor Eda2r 1.5 6.5E-01 4.7 8.5E-03 4.4 4.1E-03
nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, epsilon
Nfkbie 1.1 8.8E-01 2.1 6.2E-02 3.5 6.8E-04
mitogen-activated protein kinase kinase kinase 14 Map3k14 1.7 4.3E-01 3.5 3.0E-02 3.3 1.7E-02
nuclear factor of kappa light polypeptide gene enhancer in B-cells
2, p49/p100
Nfkb2 1.3 6.5E-01 3.6 5.6E-03 3.1 5.5E-03
lipopolysaccharide-induced TNF factor Litaf 1.7 4.1E-03 3.5 1.3E-07 3.0 5.2E-08
mitogen-activated protein kinase kinase kinase kinase 4 Map4k4 1.1 8.5E-01 3.5 9.4E-05 2.5 8.2E-04
Tnf receptor-associated factor 2 Traf2 -1.0 1.0E+00 2.8 2.1E-03 2.4 2.4E-03
interleukin-1 receptor-associated kinase 4 Irak4 1.2 2.2E-01 1.6 1.6E-03 2.2 4.0E-07
activating signal cointegrator 1 complex subunit 2 Ascc2 1.4 1.0E-01 2.4 1.2E-04 2.1 2.8E-04
TGF-b signalling
TGFB-induced factor homeobox 1 Tgif1 2.5 1.7E-03 5.7 1.1E-06 5.4 1.7E-07
follistatin Fst 1.0 9.5E-01 1.8 5.5E-02 4.1 3.5E-06
latent transforming growth factor beta binding protein 1 Ltbp1 1.2 8.0E-01 4.2 2.7E-03 4.1 9.9E-04
activin A receptor, type IIB Acvr2b -1.4 3.7E-02 -1.5 3.7E-03 -2.0 2.3E-06
activin A receptor, type I Acvr1 -1.6 6.3E-03 -2.1 2.2E-04 -2.3 5.5E-06
myostatin Mstn 1.8 1.5E-01 -5.6 5.0E-05 -3.7 2.8E-04
JAK-STAT signalling
signal transducer and activator of transcription 2 Stat2 1.2 5.4E-01 1.8 5.3E-03 2.4 1.5E-05
jun B proto-oncogene Junb 1.9 1.7E-01 1.7 2.0E-01 2.3 1.9E-02
Janus kinase 2 Jak2 1.4 9.8E-02 1.8 5.1E-03 2.2 6.8E-05
suppressor of cytokine signaling 2 Socs2 -2.6 6.6E-06 -3.5 2.9E-07 -2.1 5.0E-05
cytokine inducible SH2-containing protein Cish -3.7 3.9E-02 -6.2 3.6E-03 -4.6 5.2E-03
p38 MAPK cascade
mitogen-activated protein kinase-activated protein kinase 2 Mapkapk2 -1.2 1.4E-01 -1.9 8.2E-06 -2.2 4.4E-08
mitogen-activated protein kinase kinase 6 Map2k6 -2.4 6.7E-02 -9.4 1.6E-05 -7.0 1.6E-05
dual specificity phosphatase 1 Dusp1 -2.0 1.1E-01 -4.9 3.0E-04 -3.8 5.2E-04
dual specificity phosphatase 10 Dusp10 -3.2 7.5E-05 -1.5 1.3E-01 -1.2 4.0E-01
dual specificity phosphatase 14 Dusp14 -1.3 3.2E-01 -2.2 1.9E-03 -1.7 1.5E-02
dual specificity phosphatase 8 Dusp8 -1.9 2.7E-03 -4.5 7.8E-08 -7.1 5.4E-11
p53 signalling
tumor protein p53 inducible nuclear protein 1 Tp53inp1 2.6 2.7E-05 4.5 7.7E-08 3.9 1.2E-08
nucleophosmin (nucleolar phosphoprotein B23, numatrin) Npm1 1.4 2.4E-01 2.5 1.7E-04 2.5 5.5E-05
cytoplasmic FMR1 interacting protein 2 Cyfip2 -1.0 9.9E-01 1.1 8.4E-01 2.1 3.2E-05
Bri3 binding protein Bri3bp 1.1 6.2E-01 2.1 1.2E-04 2.1 1.6E-05
homeodomain interacting protein kinase 2 Hipk2 1.1 2.6E-01 2.0 8.7E-08 1.7 4.8E-07
tumor protein p53 inducible nuclear protein 2 Trp53inp2 -1.3 3.6E-01 -2.4 1.1E-03 -2.2 1.1E-03
FC = fold change at the three different time points (0.25-4d, 5-8d, 9-14d) with its corresponding adjusted p-value.
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NF-B signalling. TNF-a contributes to the muscle
loss through activation of the NF-B family. Several
genes (Traf2, Nfkb2, and Nfkbie) and positive activators
of this pathway Eda2r, Irak4, Ascc2, Litaf, Map4k4, and
Map3k14) were up-regulated from 5 to 14 days.
TGF-b signalling. Myostatin (Mstn), the negative reg-
ulator of muscle growth, was up-regulated 1.8 fold,
with an adjusted p-value higher than 0.05. However,
Mstn was significantly down-regulated from 5 to 14
days. The Mstn inhibitor, follistatin (Fst) was also up-
regulated in that time period (5-14d). The Mstn recep-
tors, Acvr2b and Acvr1 were down-regulated 2-fold at
9-14d and 5-14d, respectively. Other negative regula-
tors of this pathway such as Tgif1, a corepressor of
Smad2, and Ltbp1 were up-regulated 4-6-fod from 5 to
14 days.
JAK-STAT signalling. This signalling pathway was acti-
vated as indicated by the ~2-fold up-regulation of Jak2,
Stat2 and JunB from 9 to 14 days. The suppressors of
cytokine signaling, Cish and Socs2, were down-regulated
from 6 h to 14 days.
p38 MAPK cascade. Several genes of this pathway
were down-regulated, generally after 5 days: the p38
MAPK substrate, Mapkapk2/Mk2, Map2k6 and dual
specificity phosphatases (Dusp)
p53 signalling. Genes that participate in this apoptosis
pathway were mainly up-regulated from 5 to 14 days.
A schematic illustration of the major pathways that
control adult skeletal muscle size are displayed in Figure
4, i.e., genes significantly affected by the experimental
ICU intervention.
Immunofluorescence cytochemistry results
Apoptotic nuclei were visualized by staining with
cleaved caspase-3 antibody and 4´,6-diamidino-2-pheny-
lindole (DAPI). When DAPI and cleaved caspase-3 colo-
calized, the nucleus was considered apoptotic. To
determine whether the apoptotic nuclei were inside or
outside the basal lamina of the muscle, a laminin anti-
body was used. The nuclei inside laminin include both
myonuclei and satellite cells. The other nuclei were pri-
marily from endothelial cells, fibroblasts or cells related
to the immune system (Figure 5).
A small number of caspase-3 positive nuclei were
observed in the control animals (Figure 5A), but there
was a significant increase in apoptotic nuclei in the 9-
14d group, including both intramuscular and interstitial
cell nuclei (Figure 5D). There was no significant differ-
ence between the number of myonuclei per fiber
between the different groups of rats, i.e., there was no
net loss of nuclei over time. A striking finding was the
increased number of enlarged nuclei in response to
long-term immobilization and mechanical ventilation.
Validation of array results with quantitative reverse
transcription polymerase chain reaction (qRT-PCR)
In order to confirm array data, several up-regulated
(Murf1/Trim63, atrogin-1/Fbox32, Mybph, Map1lc3b)
and down-regulated (MyHC-IIa/Myh2, Mybpc) genes
were selected. In addition, Capn1 whose expression
levels did not change significantly was picked. Similar
fold-change pattern were observed between the arrays
and qRT-PCR (see Additional file 3), validating microar-
ray results.
Discussion
All critically ill ICU patients suffer from severe wasting
and impaired muscle function, which delay respirator
weaning and persist long after hospital discharge; thus,
reducing quality of life. The present results demonstrate
that the ICU muscle wasting represents unique muscle
wasting condition where multiple signalling pathways
are activated in a specific temporal pattern. In accor-
dance with our previous observations, we found that
most genes were turned on within 5 to 14 days, demon-
strating body and muscle weight, muscle fiber size, sin-
gle fiber contractile properties and contractile protein
contents are maintained during the initial four days of
the experimental ICU intervention [7].
The present results show: 1) A specific temporal pat-
tern of protein degradation pathways with an early and
maintained up-regulation of the atrogenes, followed by
an activation of the autophagy-lysosome, calpain and
ERAD protein degradation pathways at intermediate and
long durations. 2) A dramatic down-regulation of a
large number of sarcomeric proteins, including the
Figure 4 Schematic illustration of the major pathways that
control adult skeletal muscle size. Significant differentially
expressed genes playing important roles in these pathways were
mapped according to their expression level at the three time point
groups (0.25-4d, 5-8d and 9-14d); turquoise = down-regulated
genes, red = up-regulated genes and yellow = unregulated genes.
Red lines indicate inhibition and blue lines activation.
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molecular motor protein myosin, at intermediate and
long durations. 3) Activation of protein synthesis, oxida-
tive stress, several heat shock proteins/chaperones, cell
cycle arrest and pro-apoptotic genes at intermediate and
long durations. 4) Altered expression of genes involved
in the regulation of muscle size at intermediate and
long durations. 5) Activation of the caspase cascade at
the longest duration. 6) Down-regulation of the
Figure 5 Immunofluorescence cytochemistry images. A: control rats, B: 0.25h-4d, C: 5-8d and D: 9-14d. Yellow shows laminin, blue is DAPI
and green cleaved caspase-3. Arrows in A and C show apoptotic myonucleus, arrow in B shows apoptotic nucleus outside laminin, arrow in D
shows a centralized swelled nucleus that might be an activated satellite cell.
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caveolin-3, suggested to play a critical role in the altered
mechanical signalling associated with the ICU
intervention.
Protein degradation
In concordance with many other atrophy models, there
was an early (0.25-4d) and maintained (5-8d) 2-fold up-
regulation of the muscle-specific E3 ligases, atrogin-1/
Fbox32 and Murf1/Trim63, and a slightly decreased
expression at the longest duration (9-14d). Foxo1, a
member of the Foxo transcription factors, is one of sev-
eral factors activating Murf1 and atrogin-1, but the
Foxo1 activation of atrogenes was restricted to the early
phase of the experimental ICU intervention (0.25-4d).
NF-B pathway is also involved in the induction of
Murf1 [28]. Thus, after the initial Akt/Foxo activation,
the up-regulation of the NF-B pathway from 5 to 14
days is suggested to sustain the activation of Murf1 and
protein degradation.
The autophagy-lysosome system was strongly up-regu-
lated in response to the ICU intervention. Cstl1 was up-
regulated more than 10-fold between 5 and 14 days.
Runx1 and some cystatins (cathepsin inhibitors) were
highly up-regulated from 5 to 14 days, presumably to
preserve muscle mass from excessive autophagy [28],
indicating that the autophagy-lysosome system is playing
an important role in this type of muscle wasting espe-
cially at durations longer than 5 days, i.e., in accordance
with disuse atrophy [29].
The calpain system, which disassembles myofibrillar
proteins from the sarcomere to be ubiquitinated and
degraded by UPS, was activated from 5 to 14 days. The
expression of the muscle-specific isoform Capn3
decreased in response to the ICU intervention, i.e., in a
similar way as previously reported during denervation
and regeneration [30]. Capn3 is primarily involved in
regulation and sarcomere remodelling [31] and does not
contribute to the increased protein degradation.
The up-regulation of genes involved in ERAD repre-
sents a novel finding. ERADs target misfolded and unas-
sembled secretory and transmembrane proteins from
the endoplasmatic reticulum for degradation by the pro-
teasome to control protein quality and maintain cell
homeostasis [32,33].
Sarcomeric proteins
Sarcomeric protein gene expression was significantly
affected by the ICU intervention, contractile and regula-
tory proteins showed a dramatic down-regulation, pri-
marily from 5 days and onwards. In contrast to other
myosin and myosin-associated proteins, Mybph was up-
regulated 3-fold at 9-14d. We have previously observed
an increased Mybph expression in ICU patients with
AQM during recovery [34]. The function of Mybph
during atrophy and recovery is still unclear, but it may
play an essential role in the organization, maintenance
and reassembly of the thick filament.
Protein synthesis and translation factors
The translational machinery was activated from 5 to 14
days in accordance with our previous observations
showing an increased fractional protein synthesis rate at
the longer durations in the experimental ICU model [7].
These results were concordant with the dramatic decline
from day 9 to 14 of the synthesis repressor Eif4ebp;
thus, promoting translation and protein synthesis at the
latest phase of the intervention. This is in contrast to
previous observations of an Eif4ebp1 up-regulation in
response to hind limb unloading for 14 days in the rat
[29] or human fibroblasts under microgravity [35].
Thus, removal of weight bearing alone appears to have a
different effect compared with the effect of removal of
both weight bearing and the internal strain during mus-
cle contraction (mechanical silencing) associated with
the ICU intervention.
Oxidative stress response
Disuse and immobilization of skeletal muscles induce
oxidative stress and reactive oxygen species (ROS) that
activate apoptosis and proteolytic pathways [36,37]. In
response to the oxidative stress under ICU condition,
several antioxidant and chemoprotective genes were up-
regulated.
Apoptosis
From day 5 to 14, several cell cycle regulators, particu-
larly those that promote cell cycle arrest that may lead to
apoptosis [38], were up-regulated in response to the ICU
intervention, and there was also an increase of several
apoptotic genes and genes related to the p53 signalling
pathway, as well as a late up-regulation (9-14d) of the
caspase cascade. Thus, myonuclear apoptosis, as mea-
sured by the presence of cleaved caspase-3, was markedly
elevated after 9 days of the ICU intervention, but not at
earlier time-point. This is in contrast to observations of
an early (12 h) increase in the number of apoptotic myo-
nuclei in response to hind limb suspension 12 h [39].
This may also represent a fundamental difference in the
atrophy process in models removing weight bearing
alone compared with the complete mechanical silencing
in response to the ICU intervention. When comparing
the onset of myonuclear apoptosis with the onset of atro-
phy in the experimental ICU model, it becomes evident
that the atrophy precedes apoptosis.
Heat shock proteins/chaperones
A large number of chaperones that regulate cytoskeletal/
sarcomere protein folding, assembly, protein degradation
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and protection against stress were up-regulated, in con-
trast to other atrophy models of disuse and denervation
[29,40], but concordant with our previous observations
in the porcine ICU model [8]. However, in the rat ICU
model, up-regulation was significant at later durations
(5-14d) than in piglets. This may reflect a developmental
difference between the piglets, which were in an extre-
mely fast growth phase, and the young adult rats, which
had passed the rapid growth phase. Hsp90 binds to
Unc45b regulating myosin folding and assembly [41]. In
addition, both Hsp90 and Hspb8 are actively involved in
chaperone-assisted degradation pathways [42]. The up-
regulation of heat shock 105/110kDa protein (Hsph1)
from 9 to 14 days paralleled the up-regulation of cas-
pase-3 in accordance with the activation of Hsph1 by
stress conditions such as oxidative stress or endoplasmic
reticulum (ER) stress activating caspase-3 mediated
apoptosis pathways [43]. Hspb6 expression, on the other
hand, was down-regulated from 5 to 14 days and it may
have a protective role against muscle atrophy [44].
Skeletal muscle size regulators
Although some genes that promote muscle proliferation
and growth such as fibroblast growth factors, Jph1, Svil,
Vgll2 and Ky were down-regulated, a significant number
of genes that stimulate muscle size were up-regulated,
such as myogenic factors (Myog, Myf5 and Myf6).
Further, the negative regulator of muscle growth, myos-
tatin (Mstn), was down-regulated from 5 to 14 days at
the same time as its inhibitor, follistatin (Fst) was up-
regulated and the myostatin receptors (Acvr2b and
Acvr1) were down-regulated. These results are in con-
trast with observations in other muscle atrophy models
where myostatin is typically up-regulated [45-47] in line
with the increased muscle mass observed in Mstn-/-,
transgenic mice expressing a truncated form of activin
type II receptor or high levels of follistatin and mice
treated with a soluble form of activin type II receptor
[48-51]. However, a similar down-regulation of myosta-
tin was recently reported in ICU patients [52]. In addi-
tion, p38 MAPK and its downstream effector Mk2 have
been reported to be up-regulated in atrophic condition,
e.g., in patients with AQM [15], but they were found
down-regulated in our ICU model. Myostatin has been
proposed to activate p38 MAPK independently from
Smad activation [53], thus indicating a possible mechan-
ism for the inactivation of p38 pathway in this study as
well as in critically ill ICU patients.
The muscle specific caveolin-3 (Cav3) plays an essen-
tial role in sarcolemma repair and mechanotransduction
and it was down-regulated around 5-fold in our model.
Defects in Cav3 are the cause of some neuromuscular
diseases such as limb-girdle muscular dystrophy type 1C
(LGMD1C) and rippling muscle disease (RMD). It was
recently reported that down-regulation of Cav3 inhibits
the myostatin pathway [54-56]. Thus, Cav3 is suggested
to play a significant role in the altered intracellular sig-
naling associated with the mechanical silencing in the
ICU model and in the down-regulation of myostatin.
In addition, Jun B proto-oncogen (JunB), suggested to
play a role in both the maintenance and hypertrophy of
skeletal muscle mass [51], was up-regulated 2-fold after
9 days. This is different from the atrophy associated
with fasting or denervation where JunB mRNA has been
reported to be down-regulated [57,58]. Interestingly, ear-
lier studies on JunB mRNA expression in denervated
muscles have shown an up-regulation [59,60].
Taken together, these results indicate a stimulation of
genes that regulate muscle development and growth at
the longer durations (from 5 to 14 days). This is inter-
preted to reflect a compensatory mechanism to reduce
the excessive down-regulation of sarcomeric proteins
and up-regulation of different proteolytic pathways.
Conclusion
To improve our understanding of the mechanisms
underlying the muscle wasting/weakness and partial to
complete loss of myosin in limb and trunk muscles in
ICU patients with AQM, we conducted a time-resolved
(6h to 14 d) gene expression analyses using a novel
experimental rat ICU model. Novel temporal gene
expression patterns have been uncovered, demonstrating
the importance of time-resolved gene expression ana-
lyses to improve our understanding of the coordinated/
complex mechanisms underlying the muscle wasting
associated with the ICU intervention and providing new
target genes and avenues for intervention studies.
Methods
Animals and tissue collection
A total of five sham operated controls and 23 experi-
mental female Sprague-Dawley rats were included in
this study, representing a subsample from a previous
study in our laboratory [7]. The experimental rats were
anaesthetized, treated with the neuromuscular blocker
a-cobrotoxin and mechanically ventilated for durations
varying from 6h to 4 days (n = 13), from 5 to 8 days (n
= 4), and from 9 to 14 days (n = 6) (see Additional file
4). The experimental model has previously been
described in detail [61,62]. Briefly, the following surgery
and instrumentation was completed with sterile techni-
que: 1) Precordial silver wire electrocardiogram (ECG)
electrodes were implanted subcutaneously. 2) An aortic
catheter (28-gauge Teflon) was inserted via the left caro-
tid artery to record arterial blood pressure. 3) A 0.9-mm
Renathane catheter was threaded into the left jugular
vein to administer parental solutions. 4) Three subcuta-
neous EEG needle electrodes were placed into the skull
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above the right and left temporal lobes, and a third
reference electrode was placed in the neck region. 5)
Temperature was measured by a vaginal thermistor and
servo-regulated at 37°C. 6) A silicone cannula was
inserted in the urethra to continuously record urine out-
put. The sham-operated control animals underwent the
same interventions as the controls, but they were not
pharmacologically paralyzed with alpha-cobratoxin. That
is, sham operated-controls were anesthetized (isoflur-
ane), spontaneously breathing, given intra-arterial and
intra-venous solutions, and sacrificed within two hours
after the initial anesthesia and surgery.
During surgery or any possible irritating manipulation,
the anesthetic isoflurane level was at >1.5%, which
maintained the following states: 1) the electroencephalo-
gram (EEG) was synchronized and dominated by high-
voltage slow-wave activity; 2) mean arterial pressure was
100 mmHg, the heart rate, 420 beats/min, and 3) there
were no evident EEG, blood pressure or heart rate
responses to surgical manipulation. Isoflurane was deliv-
ered into the inspiratory gas stream by a precision
mass-flow controller. After the initial surgery, Isoflurane
was gradually lowered (over 1-2 days) and maintained at
<0.5% during the remaining experimental period. Rats
were ventilated through a per os coaxial tracheal can-
nula at 72 breaths/min with an inspiratory and expira-
tory ratio of 1:2 and a minute volume of 180-200 ml
and gas concentrations of 50% O2, 47% N2, and 3%
CO2, delivered by a precision volumetric respirator.
Intermittent respiratory hyperinflations (6 per hour at
15 cmH2O), positive end-expiratory pressure (1.5
cmH2O), and expiratory CO2 monitoring were continu-
ous. Neuromuscular blockade (NMB) was induced on
the first day (100 µg iv. a-cobrotoxin) and maintained
by continuous infusion (250 µg/day, iv). Mechanical
ventilation was initiated immediately after the NMB
induction. Experiments were terminated at durations
varying between 6 hours and 14 days. In no case did
animals show any signs of infections or septicemia. The
Ethical committee at Uppsala University approved all
aspects of this study.
Gastrocnemius and plantaris muscles were dissected
from the right leg immediately after euthanasia and
were quickly frozen in liquid propane cooled by liquid
nitrogen. The gastrocnemius muscle was divided into a
proximal and distal part prior to freezing. Muscle sam-
ples were stored at -80°C for further analyses. The prox-
imal part of the gastrocnemius was used for expression
profiling and quantitative RT-PCR studies. The plantaris
was used for immunofluorescence cytochemistry.
Total RNA isolation and quantification
Total RNA was extracted from frozen gastrocnemius
muscle (proximal part) tissue (10-30 mg) using a Qiagen
RNeasy® Mini Kit (Qiagen, Inc., Valencia, CA). Muscle
tissue was homogenized using a rotor homogenizer
(Eurostar Digital, IKAWerke). QIAshredder™ columns
(Qiagen Inc., Valencia, CA) were used to disrupt DNA.
Total RNA was eluted from RNeasy® Mini columns
with 30 μl of RNase-free water. RNA-concentrations
were then quantified using the fluorescent nucleic acid
stain, Ribogreen® (Molecular Probes, Eugene, OR), on
either a Chameleon PLC IIs (Hidex, Finland) fluores-
cence spectrophotometer. The same RNA preparation
was used for expression profiling and quantitative RT-
PCR.
Expression profiling
Three micrograms of total RNA from the proximal gas-
trocnemius muscle samples were extracted and pro-
cessed to generate biotin-labeled cRNA as previously
described [63]. Each sample was then hybridized to
Affymetrix Rat Gene 1.0 ST Array. The data discussed
in this publication have been deposited in NCBIs Gene
Expression Omnibus (GEO; [64]) and are accessible
through GEO Series accession number GSE30848.
Microarray data normalization and analyses
Subsequent analyses of the gene expression data was
carried out in the freely available statistical computing
language R using packages available from the Biocon-
ductor project [65]. The raw data were normalized using
the robust multi-array average [66] background-
adjusted, normalized and log-transformed summarized
values first suggested by Li and Wong in 2001 [67]. In
order to search for the differentially expressed genes
between the samples from the different days an empiri-
cal Bayes moderated t-test was applied [68], using the
‘limma’ package. A linear model was fitted to the data,
control vs. 6 h-4 days, control vs. 5-8 days, control vs. 9-
14 days. To address the problem with multiple testing,
the p-values were adjusted according to Benjamini and
Hochberg [69,70]. Probe sets with a minimum fold
change of ± 2 (log2 ratio of ± 1) and adjusted p-value <
0.05 at least in one time point were included in further
analyses. Each differentially expressed gene was flagged
by Gene Ontology (GO) classification, including mole-
cular function, biological process and cellular compo-
nent [71] (a complete gene list is included in Additional
file 2). The selected genes were grouped into a number
of clusters according to similar expression patters with
respect to time using K-means clustering analysis with
Euclidian distance carried out with Genesis software
[72]. Briefly, the K-means clustering algorithm initially
divides genes into a number of equal sized groups based
on a user-defined number (k). The centroid of each
cluster is calculated as the average of the expression
profiles. Each gene is then reassigned to the centroids
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that best match its expression pattern over time. Group
centroids are then recalculated and the process is
repeated until cluster composition converge [29,73]. In
order to estimate the optimal number of clusters, Figure
of Merit (FOM) analysis was done using Genesis soft-
ware [72] (data not shown). The transcripts contained in
each cluster were subjected to improved annotation
using DAVID web based functional annotation tool [74].
Some of the functional categories were combined and
some categorization was done manually, to improve the
interpretative value of the data (see Additional file 1).
PathwayExplorer software [75] was used to reconstruct
the most relevant signalling pathways.
Immunofluorescence cytochemistry
10 μm thick cross sections from the plantaris muscle
were cut in a cryostat at -23 °C and put onto glass
slides. The tissue sections were air dried at room tem-
perature and stored at -80°C, for later analysis. The
slides were then stained according to the following pro-
tocol: 1) Fixation: 2% PFA 15 min. 2) Washing: PBS 3 ×
5 min. 3) Permeabilization: 0.1% Triton X-100. 4) Wash-
ing: PBS 5 min. 5) Blocking: 5% normal donkey serum
and 3% horse serum 30 min. 6) Primary antibodies for
cleaved caspase-3 (rabbit anti-human, Asp1751, Cell sig-
naling, Danvers MA, 1:100), laminin (sheep anti-human,
the binding site Birmingham UK, 1:1000) and MHC
type I (1:13; mouse anti-rat, kindly provided by L.-E.
Thornell, Umeå, University) were applied with a solu-
tion containing 5% normal donkey serum, 3% horse
serum, 0.1% Triton X-100 and PBS. The sections were
incubated at 4°C for 20 h. 7) Washing: PBS 5 × 3 min.
8) Secondary antibodies for cleaved caspase-3 (Alexa
flour 488, donkey anti-rabbit, invitrogen Carlsbad CA,
1:1000), laminin (Alexa flour 633, donkey anti-sheep,
invitrogen Carlsbad CA, 1:100) and anti MHC type 1
(Alexa flour 546, donkey anti-mouse, invitrogen Carls-
bad CA, 1:1600) were applied with the same solution as
with the primary antibody. The sections were incubated
at 20°C for 60 min. 9) Washing: PBS 6 × 3 min, and 10)
the sections were mounted in vectashield mounting
medium with 4´,6-diamidino-2-phenylindole (DAPI).
Sections were scanned in a Zeiss LSM 510 confocal
microscope (Zeiss, Jena, Germany).
Quantitative RT-PCR
qRT-PCR was used to quantify the mRNA levels for rat
Myh2 (MyHC-IIa), Mybpc, Mybph, atrogin-1/Fbox32,




100 ng of total RNA from proximal gastrocnemius
muscle samples were reverse transcribed to cDNA using
Qscript cDNA supermix (Quanta Biosciences, USA).
cDNA was amplified in triplicate using MyiQ™single
color real time PCR detection system (Bio-Rad Labora-
tories, Inc., Hercules, CA, USA). The thermal cycling
conditions include 95°C for 10 minutes, followed by 50
cycles of a two-step PCR with denaturation at 95°C for
15 sec and a combined annealing and extension step at
60°C for 1 min. Each reaction was performed in a 25µl
volume with 0.4µM of each primer and 0.2µM probe.
When optimising each PCR, the PCR products were run
on 2% agarose gels to ensure that primer-dimer forma-
tion was not occurring. Taqman primers and probes
were designed using the software Primer Express®
(Applied Biosystems, Foster City, CA, USA). Primer and
probes sequences have been published elsewhere
[7,9,76] and were purchased from Thermo Electron
(Thermo Electron, Ulm, Germany). All primers and
probes were purified by high-performance liquid chro-
matography. Threshold cycle (Ct) data obtained from
running real-time RT-PCR was related to a standard
curve to obtain the starting quantity (SQ) of the tem-
plate cDNA, and the values were normalized against
18S rRNA [GenBank:AF102857].
Statistics
For qRT-PCR and immunofluorescence cytochemistry,
SigmaPlot software (Systat Software, Inc., CA, USA) was
used to generate descriptive statistics. One way analysis
of variance (ANOVA) was used to compare all groups.
When the normality test failed, a one way ANOVA on
ranks, i.e., Kruskal-Wallis one way ANOVA, was used.
A Tukey’s post-hoc contrast was performed to determine
the means that were different at the significance level of
p < 0.05; when normality failed, Dunn’s post-hoc was
used. Differences were considered significant at p < 0.05.
Additional material
Additional file 1: K-means clustering analysis. List of the genes in
each cluster and the functional categories associated to each cluster.
Additional file 2: Complete list of differentially expressed genes
affected by ICU intervention. List of 1583 significantly regulated genes
at least in one time point with their corresponding fold change and
adjusted p-value at short (0.25-4d), intermediate (5-8d) and long (9-14d)
duration, their GO classification and functional annotation.
Additional file 3: Results from qRT-PCR analyses. Validation of
microarray data by qRT-PCR. Correlation between fold changes from
microarrays and from qRT-PCR.
Additional file 4: List with the time duration for each individual rat.
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